Regeneron, Bayer’s Eye Drug Fulfills its Primary Goal
Submitted by Kamilah Qasimi on Thu, 02/18/2010 - 23:54
Regeneron Pharmaceuticals and Bayer HealthCare, a U. S. unit of Germany's Bayer, announced Thursday their experimental drug VEGF Trap-Eye, to treat retinal swelling brought on by diabetes, fulfilled its primary aim in a mid-stage study.
